- Home
- CPF vs MYGN Comparison
CPF vs MYGN Comparison
Compare CPF & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPF
- MYGN
- Stock Information
- Founded
- CPF 1954
- MYGN 1991
- Country
- CPF United States
- MYGN United States
- Employees
- CPF N/A
- MYGN N/A
- Industry
- CPF Major Banks
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- CPF Finance
- MYGN Health Care
- Exchange
- CPF Nasdaq
- MYGN Nasdaq
- Market Cap
- CPF 714.5M
- MYGN 744.7M
- IPO Year
- CPF N/A
- MYGN 1995
- Fundamental
- Price
- CPF $26.42
- MYGN $4.20
- Analyst Decision
- CPF Buy
- MYGN Hold
- Analyst Count
- CPF 1
- MYGN 16
- Target Price
- CPF $30.00
- MYGN $15.47
- AVG Volume (30 Days)
- CPF 139.3K
- MYGN 3.3M
- Earning Date
- CPF 04-23-2025
- MYGN 05-06-2025
- Dividend Yield
- CPF 4.04%
- MYGN N/A
- EPS Growth
- CPF 4.40
- MYGN N/A
- EPS
- CPF 2.14
- MYGN N/A
- Revenue
- CPF $247,706,000.00
- MYGN $831,300,000.00
- Revenue This Year
- CPF $0.31
- MYGN N/A
- Revenue Next Year
- CPF $6.15
- MYGN $6.42
- P/E Ratio
- CPF $12.48
- MYGN N/A
- Revenue Growth
- CPF 5.37
- MYGN 7.38
- 52 Week Low
- CPF $19.52
- MYGN $3.81
- 52 Week High
- CPF $33.25
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- CPF 46.42
- MYGN 33.71
- Support Level
- CPF $26.30
- MYGN $3.99
- Resistance Level
- CPF $27.24
- MYGN $4.38
- Average True Range (ATR)
- CPF 0.54
- MYGN 0.23
- MACD
- CPF -0.10
- MYGN 0.15
- Stochastic Oscillator
- CPF 18.11
- MYGN 55.00
About CPF Central Pacific Financial Corp New
Central Pacific Financial Corp operates in the financial services sector in the United States. It is a full-service commercial bank offering a broad range of banking products and services, including accepting time and demand deposits and originating loans. Bank's deposits are insured by the Federal Deposit Insurance Corporation (FDIC) up to applicable limits. The bank is not a member of the Federal Reserve System. The company's loans include commercial loans, construction loans, commercial and residential mortgage loans, and consumer loans. The company derives income from interest and fees on loans, interest on investment securities, and fees received in connection with deposits and other services.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.